Inhalation by Design: Novel Tertiary Amine Muscarinic M3Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease
Citations Over TimeTop 15% of 2011 papers
Abstract
A novel tertiary amine series of potent muscarinic M(3) receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality present in this series of compounds confers very long dissociative half-life (slow off-rate) from the M(3) receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips. Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation. Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events. Compound 47 (PF-3635659) is identified as a Phase II clinical candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.
Related Papers
- → A comparison of in vivo and in vitro methods for determining availability of iron from meals(1981)109 cited
- → The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection(2019)3 cited
- → The use of muscarinic toxins in the study of muscarinic receptors(1997)7 cited
- Pharmacokinetics and tissue distribution of Chuanhuning emuslion in rats(2014)
- 흰쥐에 있어서 톨루엔 흡입노출이 시간경과에 따른 혈중 톨루엔농도 및 행동변화에 미치는 영향(1996)